William Keller

Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Wuxi PharmaTech (Cayman), Inc. engages in the provision of research and development outsourcing services for the pharmaceutical, biotechnology and medical device industries. It operates through the laboratory services and manufacturing services segments. The laboratory services segment offers pharmaceutical and biotech services including discovery and medicinal chemistry, discovery biology, safety pharmacology, bioanalytical services, process research, formulation and toxicology laboratory services, as well as testing services for biologics, medical devices and combination products. The manufacturing services segment involves the production of intermediates and active pharmaceutical ingredients for or preclinical and clinical trials of small-molecule and commercial products; and biologics. The company was founded by Ge Li, Xiao Zhong Liu, Zhao Hui Zhang and Ning Zhao in 2000 and is headquartered in Shanghai, China.

China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.